<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00428909</url>
  </required_header>
  <id_info>
    <org_study_id>CSTI571A2107</org_study_id>
    <nct_id>NCT00428909</nct_id>
  </id_info>
  <brief_title>Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)</brief_title>
  <official_title>A Non-randomized, Open-label Study to Investigate the Effects of Imatinib Mesylate on the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A non-randomized, open-label study to investigate the effects of imatinib mesylate on the
      pharmacokinetics of acetaminophen/paracetamol in patients with newly diagnosed, previously
      untreated chronic myeloid leukemia in chronic phase (CML-CP)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the effects of the co-administration of imatinib on the pharmacokinetics of acetaminophen / paracetamol</measure>
    <time_frame>Day 1, day 2 -7, Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate the pharmacokinetic characteristics of imatinib at steady state in CML-CP patients following 400 mg dosing co-administered with acetaminophen</measure>
    <time_frame>Day 1, Day 2-7, Day 8</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Chronic Myeloid Leukemia (CML)</condition>
  <arm_group>
    <arm_group_label>Drug-Drug interaction</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib/Acetaminophen</intervention_name>
    <arm_group_label>Drug-Drug interaction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Ability to provide written informed consent prior to participation to the study.

          -  Male or female patients ≥ 18 and ≤ 75 years of age

          -  Patients with CML-CP within 6 months of diagnosis (date of initial diagnosis is the
             date of first cytogenetic analysis). FISH analysis will not be accepted.

          -  Diagnosis of CML in chronic phase with cytogenetic confirmation of Philadelphia
             chromosome of (9;22) translocations and presence of Bcr-Abl

          -  Documented chronic phase CML as defined by:

          -  &lt; 15% blasts in peripheral blood and bone marrow

          -  &lt; 30% blasts plus promyelocytes in peripheral blood and bone marrow

          -  &lt; 20% basophils in the peripheral blood

          -  ≥ 100 x 109/L (≥ 100,000 /mm3) platelets

          -  No evidence of extramedullary leukemic involvement, with the exception of
             hepatosplenomegaly

          -  Adequate end organ function as defined by:

          -  total bilirubin &lt; 1.5 x ULN

          -  SGOT and SGPT &lt; 2.5 x UNL

          -  creatinine &lt; 1.5 x ULN

          -  Female patients of childbearing potential must have a negative serum pregnancy test
             within 7 days before initiation of study drug

        Exclusion criteria:

          -  Patients in late chronic phase, accelerated phase, or blastic phase are excluded

          -  Patients who have received other investigational agents

          -  Patients who received imatinib for any duration prior to study entry

          -  Patient received any treatment for CML prior to study entry for longer than 2 weeks
             with the exception of hydroxyurea and/or anagrelide

          -  Patients with another primary malignancy except if the other primary malignancy is
             neither currently clinically significant or requiring active intervention

          -  Patients who are:

          -  pregnant

          -  breast feeding

          -  of childbearing potential without a negative pregnancy test prior to baseline

          -  male or female of childbearing potential unwilling to use barrier contraceptive
             precautions throughout the trial

          -  Post-menopausal women must be amenorrheic for at least 12 months to be considered of
             non-childbearing potential

          -  Patient with a severe or uncontrolled medical condition (i.e., uncontrolled diabetes,
             chronic renal disease)

          -  Patient previously received radiotherapy to ≥ 25% of the bone marrow

          -  Patient had major surgery within 4 weeks prior to study entry, or who have not
             recovered from prior major surgery

          -  Patients with an ECOG Performance Status Score ≥ 3

          -  Patients with International normalized ratio (INR) or partial thromboplastin time
             (PTT) &gt; 1.5 x IULN, with the exception of patients on treatment with oral
             anticoagulant

          -  Patients with known positivity for human immunodeficiency virus (HIV)

          -  baseline testing for HIV is not required

          -  Patients with any significant history of non-compliance to medical regimens or with
             inability to grant a reliable informed consent

          -  Patients with identified sibling donors where allogeneic bone marrow transplant is
             elected as first line treatment

          -  Patients who are chronic users of acetaminophen or medications containing
             acetaminophen.

          -  Patients who received acetaminophen or medications containing acetaminophen within 72
             hours prior to study entry.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmeceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2007</study_first_submitted>
  <study_first_submitted_qc>January 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2007</study_first_posted>
  <last_update_submitted>April 20, 2016</last_update_submitted>
  <last_update_submitted_qc>April 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetic</keyword>
  <keyword>STI571</keyword>
  <keyword>imatinib</keyword>
  <keyword>CML</keyword>
  <keyword>Chronic Myeloid Leukemia</keyword>
  <keyword>Philadelphia Chromosome</keyword>
  <keyword>acetaminophen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

